6533b7d6fe1ef96bd1265b6e

RESEARCH PRODUCT

A Multiplex Panel of Plasma Markers of Immunity and Inflammation in Classical Kaposi Sarcoma

Mark N. PolizzottoCarmela LauriaJames J. GoedertMeredith S. ShielsCharles S. RabkinLigia A. PintoVitale FrancescoTroy J. KempPeter Aka

subject

Malemedicine.medical_treatmentInflammationBiologySettore MED/42 - Igiene Generale E ApplicataPathogenesisKaposi SarcomaPlasma Markers of InflammationMajor Articles and Brief ReportsImmunitymedicineHumansImmunology and AllergyProspective cohort studySarcoma KaposiInflammationCase-control studyvirus diseasesPlasma Markers of Immunitymedicine.diseaseSquamous intraepithelial lesionInfectious DiseasesCytokineItalyCase-Control StudiesImmunologySarcomamedicine.symptomBiomarkers

description

Kaposi sarcoma (KS) risk is affected by perturbed immunity. Herein, we compared plasma from 15 human immunodeficiency virus (HIV)–negative classic KS cases to plasma from 29 matched controls, using a multiplex panel of immunity markers. Of 70 markers, CXCL10 (IP-10), sIL-1RII, sIL-2RA, and CCL3 (MIP-1A) were strongly and significantly associated with KS, after adjustment for age and smoking status. These and previous observations are consistent with a tumor-promoting role for these cytokines, particularly CXCL10, but the small sample size and case-control design preclude firm conclusions on KS risk or pathogenesis. Larger, well-designed prospective studies are needed to better assess the association of these markers with KS.

yearjournalcountryeditionlanguage
2014-08-24
10.1093/infdis/jiu410http://hdl.handle.net/10447/97228